BioNTech CEO Sells $2.3M in Shares Under Pre-Arranged 10b5-1 Plan
BioNTech SE
Subscribe to track BNTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
BioNTech SE (BNTX) Insider Filing
Insider: Sahin Ugur (Chief Executive Officer, 10% Owner) Action: Sold 24,000 Ordinary Shares at $95.86 per share Total Transaction Value: $2,300,632.80 Rule 10b5-1 Plan: Yes (Adopted June 3, 2026) Post-Transaction Direct Ownership: 63,209 shares Indirect Holdings (Medine GmbH): 39,218,111 shares
Comprehensive Analysis
Transaction Summary
On October 7, 2026, Dr. Ugur Sahin, Chief Executive Officer and 10% owner of BioNTech SE (BNTX), sold 24,000 Ordinary Shares directly at an average price of $95.8597 per share, generating approximately $2.30 million in proceeds.
Key Details & Context
- Rule 10b5-1 Trading Plan: The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on June 3, 2026, indicating routine liquidity management rather than a discretionary decision based on non-public developments.
- Direct vs. Indirect Holdings: Following this transaction, Dr. Sahin directly owns 63,209 ordinary shares. In addition, he holds indirect beneficial ownership of 39,218,111 shares via Medine GmbH (of which he is the sole shareholder).
- Proportional Impact: The 24,000 shares sold represent a negligible portion (less than 0.07%) of Dr. Sahin's total combined direct and indirect holdings of over 39.2 million shares.
Conclusion
Given the structured Rule 10b5-1 execution and the minuscule proportion relative to Dr. Sahin's total equity stake, this filing has low trading significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.